Lenvima® [Lenvatinib]

Brand Eisai Europe Limited

In stock 1155 Items

Available since: 2019-09-19

All payments are SSL encrypted
Full Refund if you haven't received your order
International shipping to the USA, UK and Europe

Clinical Pharmacology

Lenvatinib inhibits vascular endothelial growth factor receptor kinases VEGFR1 (FLT1), VEGFR2 (KDR), VEGFR3 (FLT4), as well as other receptor kinases involved in tumor angiogenesis or proliferation of malignant cells (including fibroblast growth factor receptors FGFRF) receptors of fibroblasts, FGFRR. , 4; platelet growth factor PDA receptor alpha receptors; KIT and RET receptors).

Indications

Lenvima® is indicated for the treatment of patients with advanced differentiated thyroid cancer, refractory to radioactive iodine.

Composition

1 caps - lenvatinib mesylate 4.9 mg, which corresponds to the content of lenvatinib 4 mg

Excipients: calcium carbonate - 33 mg, mannitol - 16.1 mg, microcrystalline cellulose - 15 mg, hyprolosis - 3 mg, low substituted hyprolosis - 25 mg, talc - 3 mg; hypromellose shell (hypromellose - 98.2%, titanium dioxide - 1.2%, iron dye yellow oxide (E172) - 0.1%, iron dye red oxide (E172) - 0.5%) - 37 mg; ink (shellac, iron dye black oxide (E172), potassium hydroxide, propylene glycol).

No customer reviews for the moment.

Write your review

Dosage and Administration

Orally, once a day at about the same time, regardless of the meal. Lenvima®a capsule should be swallowed whole with water.

Adverse reactions

Allergic reactions to the components Lenvima®a; urinary tract infection; thrombocytopenia (including a decrease in the number of platelets in the blood); loss of appetite, weight loss, hypocalcemia, hypokalemia; insomnia; headache; arterial hypertension; dysphonia, cough; diarrhea, inflammation of the oral cavity; hand erythrodestestosis syndrome; back pain, arthralgia, myalgia; proteinuria; fatigue, asthenic syndrome, peripheral edema.

Contraindications

Hypersensitivity to the active substance or other components of Lenvima®; pregnancy and breastfeeding; children's age up to 18 years (data on efficiency and safety for this category of patients are absent); chronic kidney disease in the terminal stage (data on efficacy and safety for this category of patients are not available).

Drug interactions

With simultaneous use of Lenvima® with drugs that inhibit or induce CYP3A isoenzymes and P-glycoprotein, as well as inhibit breast cancer resistance protein (BCRP), Lenvima® dose adjustment is not required.

Special instructions

In patients who received Lenvima®, arterial hypertension was recorded, which usually developed in the early stages of treatment. A sufficient control of blood pressure indicators must be achieved before starting treatment with Lenvima®. Early detection and effective treatment of hypertension is of great importance to minimize the need for a temporary suspension of drug treatment or to reduce the dose of the drug.

Overdosage

Cases of levvatinib overdose are described, including its single use at a dose of 144 mg, which is 6 times higher than the recommended daily dose of the drug. These cases were accompanied by the occurrence of undesirable reactions consistent with the studied safety profile of lenvatinib, or proceeded in the absence of reports of unwanted reactions.

Treatment: a specific antidote for overdose lenvatinib is absent. In the case of a suspected overdose, you must stop taking the drug and, if necessary, start appropriate supportive therapy.

Brand name: Lenvima®
Active ingredient: Lenvatinib
Dosage form: Capsules size No. 4, with a lid and body in red-orange color, with "знаком" applied on the lid in black ink and "LENV 4 mg" on the body; the contents of the capsules are white or almost white granules.
Manufacturer: Eisai Europe Limited
Country of Origin: Great Britain